Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ACRS vs LYRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ACRS Captures Overall Composite Edge (44.7 HOLD vs 52.2 HOLD), While LYRA Leads 3–2 on Growth & Valuation Pillars
ACRS Overall Winner
6-Pillar Tally: ACRS 2 – 3 LYRA (1 Tie)
Matrix Metrics: ACRS 6 – 1 LYRA
As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (44.7/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 6–1 (led by Growth & Scale, Profitability & Quality), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACRS trades at $3.35 (N/M Forward P/E, -1412.4% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin).
- Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ACRS 44.7/100 HOLD), ACRS captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1412.4% vs. -25032.0% operating margin) and revenue trajectory (-55.1% vs. -87.2% YoY).
- Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ACRS vs LYRA
ACRS
Head-to-Head Winner
Aclaris Therapeutics, Inc.
$3.35
-7.21% 1D
Market Cap
$621.8M
TTM Revenue
$6.4M
Forward P/E
N/M
Beta / 30D Vol
1.56β · 74% Vol
Unified Composite Score
44.7
HOLD
Tech 41.0
Fund 54.0
Flow 64.0
Mom 70.0
Weinstein Technical Phase
Markdown · Sell / avoid
LYRA
Lyra Therapeutics, Inc. Common Stock
$0.49
-62.5% 1D
Market Cap
$2.3M
TTM Revenue
$600,000
Forward P/E
N/M
Beta / 30D Vol
0.33β · 248% Vol
Unified Composite Score
52.2
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ACRS 2 – 3 LYRA)
1. Valuation Multiples
LYRA
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
97.1x
3.9x
2. Growth & Scale
ACRS
Revenue Growth (YoY)
-55.1%
-87.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$6.4M
$600,000
Market Cap
$621.8M
$2.3M
3. Profitability & Quality
ACRS
Gross Margin
N/A
N/A
Operating Margin
-1412.4%
-25032.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-55.5%
-404.5%
4. Balance Sheet & Cash Flow
LYRA
Cash Generation (TTM)
-$75M
-$32M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.11 Book/Sh · -55.5% ROE
-404.5% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
LYRA
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
60.7% (1st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ACRS (6) vs LYRA (1)| Institutional Metric | ACRS | LYRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $621.8M | $2.3M | ACRS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -55.1% | -87.2% | ACRS | |
| Operating Margin (TTM) | -1412.4% | -25032.0% | ACRS | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -55.5% | -404.5% | ACRS | |
| 52-Week Range Position | 25% ($2–$7) | 1% ($0–$38) | ACRS | |
| Beta / 30D Volatility | 1.56β · 74% Vol | 0.33β · 248% Vol | ACRS | |
| Unified Institutional Score | 44.7 / 100 (HOLD) | 52.2 / 100 (HOLD) | LYRA | |
| Trailing 12M Revenue (USD) | $6.4M | $600,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 97.1x EV/Rev | N/M PEG · 3.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$75M ($1.11 Book/Sh · -55.5% ROE) | -$32M EBITDA (-404.5% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ACRS +73.81 pp
3M Horizon
ACRS +98.93 pp
6M Horizon
ACRS +135.55 pp
1Y Horizon
ACRS +135.55 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACRS Revenue | LYRA Revenue | ACRS Op. Margin | LYRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -1378.3% | N/A | ACRS |
| FY2019 | $0M | N/A | -2627.3% | N/A | ACRS |
| FY2020 | $10M | N/A | -785.4% | N/A | ACRS |
| FY2021 | $10M | $0M | -1327.1% | -15303.5% | ACRS |
| FY2022 | $30M | $0M | -302.0% | -4131.0% | ACRS |
| FY2023 | $30M | $0M | -311.6% | -4308.1% | ACRS |
| FY2024 | $20M | $0M | -758.2% | -6280.8% | ACRS |
| FY2025 | $10M | $0M | -975.9% | -7794.5% | ACRS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ACRS
BREAKDOWN
Current IV
60.7%
IV Percentile
1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
LYRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ACRS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
LYRA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ACRS vs LYRA Key Questions & Quantitative Answers
As of Nov 17, 2026, Aclaris Therapeutics, Inc. (ACRS) captures the overall head-to-head institutional edge over Lyra Therapeutics, Inc. (LYRA) on higher Unified Composite conviction (44.7/100 HOLD vs. 52.2/100 HOLD) after splitting the core matrix 6–1 (led by Growth & Scale, Profitability & Quality), while LYRA wins 3–2 across the 6-pillar growth and valuation breakdown. ACRS trades at $3.35 (N/M Forward P/E, -1412.4% operating margin) versus LYRA at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ACRS 44.7/100 HOLD), ACRS captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-1412.4% vs. -25032.0% operating margin) and revenue trajectory (-55.1% vs. -87.2% YoY). Technical & Structure Timing Caution: ACRS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACRS leads the Growth & Scale pillar: ACRS posts -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACRS cumulative revenue shifted +0.0% while LYRA shifted N/A. In operating R&D and SG&A reinvestment, ACRS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.
LYRA screens cheaper on headline valuation multiples. ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 97.1x EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACRS (-55.5% ROE) versus LYRA (-404.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 74% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
LYRA vs ACRS · Reverse Pair
ACRS vs ANAB
· Sector Peer
ACRS vs SLDB
· Sector Peer
LYRA vs PASG
· Sector Peer
LYRA vs ORIC
· Sector Peer
LYRA vs KROS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem